VX1 Stock Overview
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VX1 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$440.60 |
| 52 Week High | US$489.20 |
| 52 Week Low | US$353.40 |
| Beta | 0.41 |
| 1 Month Change | 6.75% |
| 3 Month Change | -0.034% |
| 1 Year Change | 12.50% |
| 3 Year Change | 116.14% |
| 5 Year Change | 93.54% |
| Change since IPO | 847.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| VX1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.8% | -3.2% | 2.7% |
| 1Y | 12.5% | -7.9% | 17.0% |
Return vs Industry: VX1 exceeded the German Biotechs industry which returned -7.9% over the past year.
Return vs Market: VX1 underperformed the German Market which returned 17% over the past year.
Price Volatility
| VX1 volatility | |
|---|---|
| VX1 Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: VX1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: VX1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 6,100 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| VX1 fundamental statistics | |
|---|---|
| Market cap | €112.33b |
| Earnings (TTM) | -€510.43m |
| Revenue (TTM) | €10.50b |
10.7x
P/S Ratio-220.1x
P/E RatioIs VX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VX1 income statement (TTM) | |
|---|---|
| Revenue | US$11.02b |
| Cost of Revenue | US$1.53b |
| Gross Profit | US$9.49b |
| Other Expenses | US$10.03b |
| Earnings | -US$535.60m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | 86.11% |
| Net Profit Margin | -4.86% |
| Debt/Equity Ratio | 0% |
How did VX1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 11:18 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vertex Pharmaceuticals Incorporated is covered by 66 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |